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associated cognitive impairments. Stewart et al reported that hippocampal volume predicts delayed verbal memory function in intractable TLE. 3 White matter microstructure within the temporal lobe combined with left hippocampal volume can enhance the prediction of verbal memory impairment. 4 Even in frontal lobe epilepsy, a global decrease in functional brain connectivity was found, which comprised both connections within the frontal lobe and connections from the frontal lobe to the temporal lobe. 5 Several animal studies have also confirmed this hypothesis.
In pilocarpine-induced chronic epileptic rats, decreased expression of hippocampal m1 acetylcholine (ACh) receptor correlated to Morris water maze (MWM) test performance 6 and administration of an ACh precursor protected against cognitive impairment. 7 Adjuvant therapy with acetylcholinesterase (AChE) inhibitor improved pentylenetetrazole-kindling-induced learning and memory deficits in mice. 8 However, the cholinergic system comprises a series of proteins in the synthesis, storage, transportation, and degradation of ACh. The exact role of the cholinergic system in epilepsy-associated cognitive decline remains unknown. Vesicular ACh transporter (VAChT) is a limiting factor in uptake of ACh into cholinergic synaptic vesicles and has major influence on ACh release. 9 Compared with other cholinergic markers such as acetyltransferase (ChAT) and AChE, VAChT has a unique value in unraveling the specific contribution of ACh, as ChAT-labeled cholinergic neurons corelease other neurotransmitters such as glutamate 10 and AChE stains the monoaminergic in addition to the cholinergic system. 11 Previous studies have used VAChT as a molecular imaging biomarker in neurodegenerative diseases. Using 123 I-iodobenzovesamicol single photon emission computed tomography, decline of VAChT in central cholinergic pathways has been found in neurodegenerative diseases such as dementia with Lewy bodies. 12 Because the neurotransmitter is loaded into synaptic vesicles by VAChT, 9 and change of glutamatergic synapses, which are closely related to cholinergic synapses, underlies epilepsy-associated cognitive deficits, 13 we hypothesized that the VAChT is a specific cholinergic marker that declines in major sectors of the cholinergic pathway in epilepsy and correlates to epilepsy-associated cognitive decline. We used [ 18 F] VAT, a new 18 F-labeled carbonyl-containing benzovesamicol analogue as a novel positron emission tomography (PET) tracer for quantifying VAChT that has high affinity and selectivity for VAChT. 14 This compound is based on vesamicol, which noncompetitively inhibits the transport of ACh through binding to VAChT and has served as the lead structure in the development of VAChT radioligands. 14 
| MATERIALS AND METHODS

| Animals and pilocarpine-induced chronic epilepsy model
We totally included 32 male Sprague-Dawley rats (SLRC Laboratory Animal Corporation, Shanghai, China; 200-250 g), of which seven were randomly assigned into a control group and 25 were used to prepare the pilocarpineinduced epilepsy model. All rats were housed for 1 week before the experiment and maintained under controlled environmental conditions (22 ± 2°C, humidity = 40%-70%, 12-hour light/dark cycle) with free access to food and water. Racine scale lasting for >30 minutes that were terminated by diazepam (10 mg/kg). In our study, 23 rats developed acute SE. Rats in the control group were injected ip with the same dose of lithium chloride and scopolamine, but saline was used instead of pilocarpine. One week after SE, surviving rats underwent 2-week continuous video monitoring to detect spontaneous recurrent seizures (SRS). The chronic period was defined as the period after two or more SRS that reached stage 4-5 had occurred. In our study, 13 rats survived SE and nine rats met the criteria for the chronic epilepsy model. As two chronic epileptic rats died during the chronic period, seven rats were included in the subsequent study.
| MWM test
The MWM test was carried out 12 weeks after SE. To avoid effects of SRS on the outcome of the MWM test, we conducted continuous video monitoring from 2 hours before and during the test to verify that no seizures had developed. The MWM test included five consecutive days of acquisition test and probe test on the sixth day. On each day of the acquisition test, the rats were released successively into water from four different quadrants. The rats finding the platform within 120 seconds were left there for 15 seconds. Those failing to do so were guided toward the platform and left there for 15 seconds. In the probe test, the platform was removed and the rats were allowed a 30-second swim from a novel start position. The rats' movements were monitored with a video camera and analyzed by a video tracking system (Ethovision XT 8.5; Noldus Information Technology, Wageningen, The Netherlands). The swim velocities were calculated. In the acquisition test, mean escape latency to the platform of four trials on each training day was measured. In the probe test, three measures (duration in target quadrant, mean distance to the former zone of the platform, and the number of crossings over the former location of the platform) were analyzed. We included a total of 10 ROIs 15 ( Figure S1 and Table S2 ). Specifically, the central cholinergic pathway can be subdivided into six main sectors (Ch1-Ch6). 16 First, septum including Ch1 and Ch2 sectors provides the major cholinergic projections of hippocampus. Entorhinal cortex also receives cholinergic innervations from Ch1 and Ch2 sectors and is connected to hippocampus. 15 Second, basal forebrain includes Ch1-Ch4 sectors. Among them, Ch4 sector provides the major cholinergic innervations of amygdala and cortex such as prefrontal cortex, which includes cingulate cortex, medial prefrontal cortex, and orbitofrontal cortex. Third, thalamus receives cholinergic fibers from Ch5 and Ch6 sectors. In addition, we analyzed the caudate and putamen region, which is rich in cholinergic interneurons. 17 The standardized uptake value of each ROI was calculated and normalized to pons.
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| Western blot
After PET scans, rats were intracardially perfused with 200 mL of 4°C phosphate-buffered saline and the hippocampus and basal forebrain were dissected out on ice and stored at −80°C. Protein concentrations were determined by Bicinchoninic Acid Protein Assay Kit (Beyotime, Haimen, China). Samples were separated by standard sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membrane (Millipore, Billerica, Massaachusetts). The following primary antibodies were used: rabbit anti-VAChT (1:500; Sigma), rabbit anti-ChAT (1:500; Invitrogen, Carlsbad, California), and mouse anti-β-actin (1:1000; Beyotime). The optical density of three samples in each rat was analyzed.
| Determination of AChE activity
The hippocampus and basal forebrain were dissected and homogenized and then centrifuged at 4000 rpm at 4°C for 10 minutes. The supernatant was collected. AChE activity of three samples in each rat was determined using a commercial kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) and expressed as optical density per milligram protein measured at 412-nm wavelength.
| Cresyl violet and immunofluorescence staining
After PET scans, half of the rats were intracardially perfused with phosphate-buffered saline followed by 4% paraformaldehyde at 4°C. The brains were prepared for frozen coronal sections, which were cut with a thickness of 10 μm in adjacent series. All sections were processed under identical conditions and made on roughly the same section of the brain for each rat. For cresyl violet staining, the sections were stained with cresyl violet acetate (0.1%) for 15 minutes. For immunofluorescence staining, the sections were incubated in 5% goat serum for 1 hour and followed by primary antibody: rabbit anti-VAChT (1:250; Sigma) in phosphate-buffered saline at 4°C overnight. The sections were incubated with secondary antibody (antirabbit, Alexa 488, 1:800; Invitrogen) for 1 hour at room temperature. Nuclei were stained with 4,6-diamidino-2-phenylindole (1:1000; Sigma). Controls were routinely carried out by replacing the primary antisera with normal sera from the same species and at the same concentration. Slides were examined by fluorescence and confocal microscopy. 
| RESULTS
| Pilocarpine-induced chronic epileptic rats exhibited learning and memory deficits
During the 2-week monitoring period, the average number of SRS was 14.0 (SEM = 1.4). On the MWM, we first observed a significantly higher swim velocity in the epilepsy group compared with the control group on the acquisition test (P < 0.001) and the probe test (P = 0.026; Figure 1A ). On the acquisition test, both groups showed a progressive reduction of average escape latency during the training period of five consecutive days, and a significant elevation (P = 0.024) of escape latency was observed in the epilepsy group ( Figure 1B) . On the probe test, the epilepsy group exhibited remarkably poorer performance than the control group, with shorter duration in the target quadrant (P = 0.006), longer distance to the former zone of the platform (P = 0.012), and fewer number of crossings over the former location of the platform (P = 0.002; Figure 1C -E). ] VAT was achieved with an overall radiochemical yield of 20%-30%, specific activity > 20 GBq/μmol, and radiochemical purity > 99% (n > 10). [ 18 F] VAT uptake in rats' total brain reached maximum at 5 minutes postinjection, and decreased gradually over 240 minutes postinjection, declining fast initially and then slowing down, reaching a relatively stable plateau after 25 minutes ( Figure S2 ). Considering that the initial peak may be associated with nonspecific uptake, we chose the 25-minute time point for further analysis.
The highest uptake of [ 18 F] VAT was observed in caudate and putamen (Table S1 ). Uptake of [ 18 F] VAT in the epilepsy group decreased at the subcortical level compared with the control group. The greatest decrease was observed in septum (23.4%) and hippocampus (15.8%), followed by caudate and putamen (14.7%), amygdala (14.0%), thalamus (11.3%), F I G U R E 1 Impaired learning and memory of pilocarpine-induced chronic epileptic rats on the Morris water maze test. A, Higher swim velocities in epilepsy group. B, Progressive reduction of escape latency in both groups and elevated escape latencies in the epilepsy group on the acquisition test. C-E, Shorter duration in target quadrant, longer distance to the former zone of the platform, and fewer number of crossings over the former location of the platform for the epilepsy group on the probe test. Values are mean (standard error of the mean) or median (interquartile range). *P < 0.05, **P < 0.01, 
| Expression of VAChT decreased in hippocampus and basal forebrain in epilepsy group, whereas no change of expression of ChAT or activity of AChE was detected
In Western blot and AChE activity analysis, decreased expression of VAChT in hippocampus and basal forebrain was confirmed in the epilepsy group, whereas no significant difference in the expression of ChAT or activity of AChE was detected ( Figure 3 ). Cresyl violet staining showed decreased neuronal cell counts in all analyzed regions in the epilepsy group ( Figure S3 ). Immunofluorescence staining showed decreased expression of VAChT in amygdala, thalamus, septum, cornu ammonis 1 and 3 subregions of hippocampus, Ch1-Ch3 sectors of basal forebrain, and caudate and putamen in the epilepsy group (Figure 4 ). In our study, chronic epilepsy is induced in rats by systemic administration of lithium-pilocarpine as a recognized model of TLE. We performed the MWM test 12 weeks after SE, and our results verified that chronic epileptic rats presented with learning and memory deficits, which was consistent with previous reports. 19 The pilocarpine model reproduces comorbidities of human TLE 20 and allows for identification of long-term neurochemical and behavioral changes underlying seizure-induced cognitive damage. 21 Previous neuroimaging studies have revealed structural alterations related to behavioral impairment and aberrant hippocampal neurogenesis that contributed to cognitive deficits in the pilocarpine model, 22 but the underlying mechanisms of such deficits are not yet fully understood. Although progress has been made in imaging neurodegenerative diseases, a molecular imaging marker for epilepsy-associated cognitive impairment is still lacking. By using [ 18 F] FDG PET, previous researchers have found hypometabolism in both temporal and frontal lobe in intractable mesial TLE patients, yet only the former was associated with cognition. 23 VAT was used to provide direct information about the cholinergic system. VAChT plays a critical role in the regulation of cognitive function. In Alzheimer's disease patients, level of VAChT declined in prefrontal cortex 26 and temporal cortex. 27 In genetically modified mice targeting VAChT, information acquisition correlated to level of hippocampal VAChT and selective decreasing hippocampal VAChT resulted in synaptic plasticity disturbance and working memory impairment. 28 Overexpression of VAChT enhances dendritic complexity of adult-born hippocampal neurons and improves acquisition of spatial memory during aging. 29 In our study, decline of VAChT in the epilepsy group and a positive correlation between VAChT level and memory function were found in most sectors of cholinergic pathway, which indicates a crucial role of cholinergic dysfunction in epilepsy-associated cognitive deficits. Our results suggest that all of the Ch1-Ch6 pathways were affected and the most obviously disturbed was Ch1 and Ch2, representing a septohippocampal network, in which cholinergic neurons participate in the generation of theta oscillations. 30 In chronic epilepsy, the septohippocampal network is altered. 31 The death of septal neurons may contribute to network rewiring. This could result in disturbance of theta oscillations, which play a key role in cognitive function. 30 Contrary to our results, in dementia with Lewy bodies, 123 I-iodobenzovesamicol single photon emission computed tomography scan of VAChT demonstrated significantly lower nondisplaceable binding potential values in the Ch4 and Ch5 pathway both at cortical and subcortical levels, whereas the Ch1 pathway was relatively preserved. 12 The distinct pattern of cholinergic dysfunction suggests a pathogenesis of cognitive deficits in epilepsy different from neurodegenerative diseases such as dementia with Lewy bodies, which deserves further investigation.
| DISCUSSION
To the best of our knowledge, our study is the first to report basal forebrain cholinergic neuronal injury in an epilepsy model. Basal forebrain cholinergic neurons are major components of Ch1-Ch4 sectors innervating the hippocampus and cortex, which play a significant part in spatial and working memory. 32 In a previous report, elimination of VAChT in basal forebrain caused deficits in spatial memory, long-term potentiation, 33 which indicates the specific contribution of forebrain cholinergic tone for modulating cognition. Nevertheless, whether basal forebrain neuronal dysfunction plays a part in epilepsy-associated cognitive Concerning the caudate and putamen region, our results did not reveal correlation between level of VAChT and memory function. The reason could be that we analyzed the level of VAChT throughout the entire striatum region, but only a portion of the cholinergic interneurons in the striatum are involved in cognition. 17 It has been demonstrated that synaptic dysfunction is involved in epilepsy-associated cognitive deficits. In TLE patients, poor memory performance correlates to hippocampal expression of molecules associated with synaptic function. 34 One possible explanation could be upregulation of proinflammatory pathway that impairs synaptic plasticity in seizure. 35 Changes in glutamatergic synapses have been detected in rats after kainic acid-induced early life seizure with loss of long-term potentiation and enhanced long-term depression. 13 Cholinergic neurons coexpress vesicular glutamate transporters in synaptic vesicles, which facilitates ACh filling these vesicles 9 ; this indicates a close relationship between the glutamatergic and cholinergic systems. Moreover, altered expression of vesicular glutamate transporters in TLE patients 36 and following pilocarpine-induced seizure 37 has been reported. This has led us to suspect that presynaptic cholinergic neuromodulation is also altered and contributes to memory deterioration in epilepsy.
Because treatments for cognitive deficits in epilepsy have been largely unsatisfactory, research in pursuit of targeted drugs is of great clinical importance. 38 In a pilot study of patients with epilepsy, verbal short-term memory was improved by donepezil, 39 but other studies failed to demonstrate its benefit. 40 The inconsistent results might be related to the heterogeneous nature of study subjects, so
F I G U R E 3 Expression of vesicular
acetylcholine transporter (VAChT) and acetyltransferase (ChAT) and activity of acetylcholinesterase (AChE) in hippocampus and basal forebrain. Western blot and AChE activity analysis shows decreased expression of VAChT in the epilepsy group (A, D), whereas no significant difference in the expression of ChAT (B, E) or activity of AChE (C, F) was detected. *P < 0.05, **P < 0.01 epilepsy group versus control group. mgprot, milligram of protein further research is required to determine whether individual patients would benefit from AChE inhibitors. In this sense, we suggest [ 18 F] VAT PET could serve as a promising imaging test to select patients with cholinergic dysfunction appropriate for AChE inhibitor treatment in the future. The present study has some limitations. First, as we used a long-term chronic epilepsy model with a relatively high mortality rate, the sample size was rather small. Second, our selection of ROIs could not cover all parts of the cholinergic system. Third, to avoid possible radiation artifact by high uptake of the striatum, the dose of [ 18 F] VAT injection is limited. To compensate for this limitation, we used PMOD software for automated data postprocessing and uptake of each ROI was normalized to pons. Fourth, our study shows extensive neuronal loss besides the cholinergic system. Other mechanisms such as the glutamatergic dysfunction may also participate in epilepsy-associated cognitive deficits, which deserve further research. Lastly, our preliminary results merit further study in patients with epilepsy.
In summary, our study demonstrated decreased VAChT in major sectors of the central cholinergic pathway associated with spatial memory deficits. Our results indicated [ 18 F] VAT PET could be a promising method to test the level of VAChT as a valuable biomarker for memory deficits in pilocarpine-induced chronic epileptic rats, which may provide therapeutic value.
